anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Study is a randomized, double-blinded, placebo-controlled, Phase II clinical trial. Participants will be recruited while attending regularly scheduled clinic appointments at the Jackson VA Medical Center. Baseline Visit. Participants will be randomized 1:1 in groups of 10 to receive valacyclovir 1.5 gram orally twice daily or matching placebo. Enrolled participants will complete 12 weeks of assigned therapy.

At the initial visit, participants will complete a short questionnaire detailing past medical/social history and relevant symptoms. Venipuncture will be performed to obtain samples for the laboratory tests. The baseline de-identified serum sample will be obtained from the clinical lab and stored in research-approved freezer space for future confirmation with the Biokit HSV-2 rapid assay. Follow-up visits will be scheduled at two-week intervals after baseline. At each visit, pill-count, compliance and tolerability of medications will be assessed using a short questionnaire. Venipuncture will be performed every four weeks (i.e., at every other follow-up visit) to provide samples for the tests described below. Information from each study visit will be recorded into the chart by the PI or Research Assistant (RA) and entered into an encrypted database on a VA server. Laboratory Tests. HSV-2 infection will be confirmed by performing the Biokit HSV-2 rapid assay on the baseline stored serum sample using methods previously described in this proposal. Laboratory tests will include 1) complete blood count, comprehensive metabolic profile, and quantitative hepatitis C virus (HCV) RNA; and 2) Focus HerpeSelect HSV-1 Immunoglobulin G (IgG) for participants who were seronegative for HSV-1 at baseline. Patient's IL28-B genotype will also be assessed at baseline. The PI will review all laboratory parameters.

Baseline characteristics between the groups will be compared using appropriate parametric tests. Analysis will be intention to treat with the inclusion of all subjects who were randomized to drug or placebo. The primary outcome is change in HCV viral load in the treatment group compared with placebo. Because the investigators are expecting a 0.5 log10 decline in HCV viral load, the investigators will use one-sided parametric tests. All viral loads will be log10-transformed before analysis.
The combination of systemic metronidazole (MTZ) and amoxicillin (AMX) to scaling and root planing (SRP) has shown to be a promising periodontal treatment. However, some essential issues associated with the use of these antibiotics remain to be established. Although these agents are often prescribed after the healing phase of the SRP procedure, there is biological plausibility to support its use in conjunction with the mechanical treatment. However, to date, no placebo controlled randomized clinical trial (RCT) has directly compared these two protocols. Therefore, the aim of this multicentric RCT is to compare the clinical, microbiological and immunological effects of adjunctive systemic MTZ+AMX administered in different phases of the treatment of generalized chronic periodontitis (GChP). 180 subjects with GChP will be randomly assigned into three groups (n=60/group) that will receive SRP-only (control group) or in combination with 400 mg MTZ+500 mg AMX beginning at the first SRP session (group test 1) or after 3 months of its completion (group test 2). All volunteers will receive clinical and microbiological evaluation at baseline, 3, 6 and 12 months, and immunological assessment (levels of 20 chemokines) at baseline and 12 months post-therapy. Nine subgingival biofilm samples will be collected by subject and analyzed for counts and proportions of 40 bacterial species by checkerboard DNA-DNA hybridization. Differences in clinical, microbiological and immunological parameters among groups and over time will be evaluated using the ANOVA, ANCOVA, Chi-square and Tukey tests. Microbiological analyzes will be performed using adjustments for multiple comparisons. Statistical significance will be set at 5%.
Strength training of the oral and pharyngeal muscles is performed in group, led by an occupational therapist. Training for 3 months.
The invention relates to a method for preparing a tetrodotoxin-degrading substance from a tetrodotoxin-producing bacteria fermentation broth, and a preparation and detection method of an extract liquid. The method comprises a method for artificially causing plasmid loss, a tetrodotoxin-degrading substance extraction method, and a tetrodotoxin degradation detection method. According to the invention, for a first time, the existence of a tetrodotoxin-degrading substance in aeromonas molluscorum is found, and an extraction method of the substance is established. The method has certain potential to be used in large-scale productions of the tetrodotoxin-degrading substance. The extract of the bacteria fermentation broth has a tetrodotoxin-degrading effect, and can be used for preparing medicines used for treating tetrodotoxin intoxication. Also, a raw material can be provided for related fields such as scientific research and pharmaceutical industries.
PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation. 30 minutes structural MRI will be obtained to permit co-registration of PET images.
BACKGROUND: Early pregnancy nutritional status can be associated with adverse birth outcomes such as small-for-gestational age (SGA) and low birth weight (LBW). BMI (Body Mass Index) and MUAC (Mid-upper arm circumference) are easy to use assessments and are indicative of the pre-pregnancy nutritional status if obtained in the first trimester. This study primarily assesses the association of maternal nutritional status using BMI and MUAC with SGA in a community-based cohort of Pakistani women. It also aims to determine the predictive ability of MUAC and BMI in predicting SGA. Secondarily, we assessed the association between maternal nutrition and large for gestational age (LGA) and LBW.
METHODS: This study is a secondary analysis of an ongoing pregnancy cohort "Pregnancy Risk Infant Surveillance and Measurement Alliance (PRISMA)"in Ibrahim Hyderi and Rehri Goth, Karachi. PRISMA participants who were enrolled between January 2021 to August 2022 were included given they had a gestational age < 14 weeks confirmed via ultrasound, MUAC and BMI measurements were available and birth weight was captured within 72 hours. Multivariable logistic regression was used to determine an association between maternal nutritional status and SGA. The PRISMA study was approved by the Aga Khan University Ethics Review Committee (2021-5920-15,518).
RESULTS: Of 926 women included in the analysis, 26.6% (n = 247) had a low MUAC (< 23 cm) while 18.4% (n = 171) were underweight (BMI < 18.5 kg/m2). Nearly one third of low MUAC and underweight women delivered SGA infants (34.4 and 35.1% respectively). Underweight women and women with low MUAC had a statistically significant association with SGA (Underweight: OR 1.49, 95% CI 1.1,2.4; Low MUAC-OR 1.64, 95% CI 1.2,2.3) as well as LBW (Underweight: OR-1.63, 95% CI 1.1,2.4; Low MUAC-OR-1.63, 95% CI 1.2,2.3). ROC curves showed that MUAC and BMI had modest predictability for SGA (AUC < 0.7).
CONCLUSION: Maternal nutritional status as indicated by BMI and MUAC are strongly associated with adverse pregnancy outcomes including SGA, LGA and LBW. Although MUAC and BMI are widely used to determine maternal nutritional status, they have poor predictive ability for newborn size. Further research is needed to identify other tools or a combination of tools to better predict adverse birth outcomes in resource-limited settings and plan interventions.
The relevance of aberrant serum IgG N-glycosylation in liver fibrosis has been identified; however, its causal effect remains unclear. Because hepatic stellate cells (HSCs) contribute substantially to liver fibrosis, we investigated whether and through which mechanisms IgG N-glycosylation affects the fibrogenic properties of HSCs. Analysis of serum IgG1 N-glycome from 151 patients with chronic hepatitis B or liver cirrhosis revealed a positive correlation between Ishak fibrosis grading and IgG1 with agalactosyl N-glycoforms on the crystallizable fragment (Fc). Fc gamma receptor (FcγR) IIIa was observed in cultured human HSCs and HSCs in human liver tissues, and levels of FcγRIIIa in HSCs correlated with the severity of liver fibrosis. Additionally, agalactosyl IgG treatment caused HSCs to have a fibroblast-like morphology, enhanced migration and invasion capabilities, and enhanced expression of the FcγRIIIa downstream tyrosine-protein kinase SYK. Furthermore, agalactosyl IgG treatment increased fibrogenic factors in HSCs, including transforming growth factor (TGF)-β1, total collagen, platelet-derived growth factor subunit B and its receptors, pro-collagen I-α1, α-smooth muscle actin, and matrix metalloproteinase 9. These effects were more pronounced in HSCs that stably expressed FCGR3A and were reduced in FCGR3A knockout cells. Agalactosyl IgG and TGF-β1 each increased FCGR3A in HSCs. Furthermore, serum TGF-β1 concentrations in patients were positively correlated with agalactosyl IgG1 levels and liver fibrosis severity, indicating a positive feedback loop involving agalactosyl IgG, HSC-FcγRIIIa, and TGF-β1. In conclusion, agalactosyl IgG promotes fibrogenic characteristics in HSCs through FcγRIIIa. © 2024 The Pathological Society of Great Britain and Ireland.
This phase II clinical trial will enroll patients with newly-diagnosed locally-advanced pancreatic adenocarcinoma and adopt the Simon's two-stage optimum design. After 4 cycles of SIROX regimen, patients will proceed to curative resection. The primary endpoint of this study is resection rate after neoadjuvant chemotherapy. The first stage will enroll 18 patients. We will go into the second stage if at least 2 patients in stage I become resectable after treatment. There will be at most 35 patients enrolled. Based on this trial, we anticipate that the SIROX regimen has comparable response rate and resection rate but lower toxicities comparing to FOLFIRINOX.
Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2197870A vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2 and a booster dose of Menitorix™ vaccine at Month 10. All vaccines were administered intramuscularly. GSK2197870A and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh.
The following are claimed: (A) a liposomal compsn. contg. an enzyme having L-Asparaginase activity, characterised by having a protein/lipid ratio of at least 30 mcg/micromol, the size of the liposomes being up to 1000 nm; the enzyme may be an L-Asparaginase deriv. e.g. palmitoyl-L-Asparaginase. (B) a process for preparing a liposomal compsn. contg. L-asparaginase characterised by (a) forming multilamellar liposomes from an aq. soln. of the enzyme and the lipid, (b) lyophilising the resulting liposomes, (c) rehydrating the lyophilised liposomes by treatment with a small vol. of a non-saline suspending fluid, followed, after a resting phase, by (d) treatment with a saline soln., (e) diluting the resulting suspension and (e) extruding the suspension under pressure without prior sepn. of non-incorporated enzyme. (C) a process for incorporation of a hydrophobic protein into liposomes characterised by (a) adding the protein in dry form to preformed multilamellar liposomes which are either empty liposomes or contain a hydrophilic protein in their aq. phase, (b) lyophilising the mixt. and rehydrating the lyophilised material to reconstitute liposomes and (c) filtering under pressure to reduce size. The lipids may be e.g. distearoylphosphatidylcholine (DSPC), phosphatidylcholine (PC), cholesterol, sphingomyelin, dioleoylphosphatidylcholine (DOPC), etc.
A ferrous calcium citrate complex having the empirical formula Fe(CaC6H5O7)2 and containing water of hydration is obtained by adding metallic iron to an aqueous solution of monocalcium citrate, heating the mixture to the boil and refluxing to form the complex which is precipitated and removed.  The invention also comprises as a new product a ferrous calcium citrate complex having the empirical formula Fe(CaC6H5O7)2.4H2O.  The mono-calciu citrate may be obtained by reacting citric acid with an equimolar amount of calcium base such as calcium carbonate, calcium oxide, or calcium hydroxide, in aqueous solution.  In an example an aqueous suspension of finely-powdered calcium carbonate is added, with agitation, to an aqueous solution of citric acid monohydrate at room temperature and reduced powdered iron is then added slowly and the mixture stirred, heated to boiling, refluxed, and then filtered while hot to yield as residue on the filter a colourless complex having the empirical formula Fe(CaC6H5O7)2.4H2O.  The complex containing water of hydration is stated to be effective as a source of calcium and iron in the diet and may be uniformly distributed in a carrier and formed into tablets (see Group VI).ALSO:The invention comprises a composition of matter for oral administration effective as a source of calcium and iron in the diet which includes in a carrier, a ferrous calcium nitrate complex containing water of hydration prepared by adding metallic iron to an aqueous solution of monocalcium citrate, heating the mixture to the boil and refluxing whereby the complex is formed and precipitated (see Group IV(b)).  The complex specified is one having the empirical formula Fe(CaC6H5O7)2. 4H2O.  The complex may be uniformly distributed in the carrier and formed into a tablet. Specified inert solid diluents or fillers which may be present are lactose, dextrose, sucrose, sodium chloride, glycine, kaolin and starch.  It is desirable that a binder such as acacia, zein, tragacanth, gelatine, sodium carboxymethyl cellulose, or methyl cellulose and a lubricant such as magnesium stearate, zinc stearate, mineral oil, stearic acid, stearyl alcohol, or mono- and polyglycol esters also be present.  The ratio of calcium to iron in the formulation may be increased or decreased by the addition of agents such as tricalcium citrate or ferrous citrate.  In examples tablets are formed from the above specified complex and dipotassium phosphate, acacia, magnesium stearate and lactose with and without cellulose acetate-phthalate.
The key function of TNAP in bone is degradation of PPi to remove this mineralization inhibitor and provide free phosphate for apatite deposition. PC-1 is a direct antagonist of TNAP function. ANK antagonizes TNAP-dependent matrix calcification. Specifically, the activity of PC-1 inhibits initial MV apatite deposition, but ANK inhibits propagation of apatite outside the MVs. Furthermore, loss of function of the two distinct skeletal TNAP antagonists, PC-1 and ANK, ameliorates TNAP deficiency-associated osteomalacia in vivo. Conversely, the hyperossification associated with both PC-1 null mice and ANK-deficient (ank/ank) mice is ameliorated by deficiency of TNAP in vivo.
Lisinopril can cause symptomatic hypotension, sometimes complicated by oliguria, progressive azotemia, acute renal failure or death. Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology.

In these patients, lisinopril should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of lisinopril and/or diuretic is increased. Avoid use of lisinopril in patients who are hemodynamically unstable after acute MI.

Symptomatic hypotension is also possible in patients with severe aortic stenosis or hypertrophic cardiomyopathy.

Surgery/AnesthesiaIn patients undergoing major surgery or during anesthesia with agents that produce hypotension, lisinopril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.
PURPOSE: To obtain an antineoplastic agent comprising a combination of a specific polyamine compound and a cytotoxic agent and capable of manifesting a synergistic effect. CONSTITUTION: This cancer treating agent comprises (A) an antineoplastically effective amount of N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine, and (B) an antineoplastically effective amount of cytotoxic agent selected from vinca alkaloids of antineoplastic agent (e.g. vinblastine and vincristine), an antibiotic (e.g. adriamycin and daunorubicin), an antimetabolite (e.g. methotreaxate and cytarabline) and a platinum complex (e.g. cisplatin and carboplatin), and is administered simultaneously or sequentially. Leukemia, cancer, lymphoma and osteosarcoma are treated, when the vinblastine is used as the component B in the above combination, and the treating agent is especially effective to the treatment of the cancer, testis teratocarcinoma and ovarian cancer, when the cisplatin is used.
OBJECTIVE: Surgery can effectively treat Trigeminal neuralgia (TN), but postoperative pain recurrence or nonresponse are common. Repeat surgery is frequently offered but limited data exist to guide the selection of salvage surgical procedures. We aimed to compare pain relief outcomes after repeat microvascular decompression (MVD), percutaneous rhizotomy (PR), or stereotactic radiosurgery (SRS) to determine which modality was most efficacious for surgically refractory TN.
METHODS: A PRISMA systematic review and meta-analysis was performed, including studies of adults with classical or idiopathic TN undergoing repeat surgery. Primary outcomes included complete (CPR) and adequate (APR) pain relief at last follow-up, analyzed in a multivariate mixed-effect meta-regression of proportions. Secondary outcomes were initial pain relief and facial numbness.
RESULTS: Of 1299 records screened, 61 studies with 68 treatment arms (29 MVD, 14 PR, and 25 SRS) comprising 2165 patients were included. Combining MVD, PR, and SRS study data, 68.8% achieved initial CPR after a repeat TN procedure. On average, 49.6% of the combined sample of MVD, PR, and SRS had CPR at final follow-up, which was on average 2.99 years postoperatively. The proportion (with 95% CI) achieving CPR at final follow-up was 0.57 (0.51-0.62) for MVD, 0.60 (0.52-0.68) for PR, and 0.35 (0.30-0.41) for SRS, with a significantly lower proportion of pain relief with SRS. Estimates of initial CPR for MVD were 0.82 (0.78-0.85), 0.68 for PR (0.6-0.76), and 0.41 for SRS (0.35-0.48).
CONCLUSIONS: Across MVD, PR, and SRS, about half of TN patients maintain complete CPR at an average follow-up time of 3 years after repeat surgery. In treating refractory or recurrent TN, MVD and PR were superior to SRS in both initial pain relief and long-term pain relief at final follow-up. These findings can inform surgical decision-making in this challenging population.
INTRODUCTION: The intra-aortic balloon pump (IABP) is one of the most utilized cardiac assist devices. Patients receiving IABP therapy are typically managed in high acuity clinical care areas with limited bed space and high demand. Our center instituted a certified clinical perfusionist (CCP) led initiative to remove IABP catheters in order to reduce IABP therapy time, hasten removal and improve efficiency.
METHODS: The purpose of the study is to compare outcomes for IABP removal by a certified clinical perfusionist to a physician. The primary outcome measures were site hematoma score and limb related complications. A survey was submitted to bedside nurses, managers/patient care coordinators, CCP's and physicians. The IABP quality assurance database was interrogated for the study.
RESULTS: There were 350 patients eligible for inclusion. The cohort was well balanced between CCP (n = 284) and physician (n = 66) groups for patient demographics, indication, insertion specifics and type of medical intervention. The majority of patients had no bruise or hematoma with perfusionist (n = 246, 87%) or physician (n = 58, 88%) (p = 0.78) removal. The physician group demonstrated a higher rate of grade 3 hematomas (p = 0.03). There was no statistically significant difference between CCP and physician groups for limb complications and mortality. Survey results showed an improved efficiency in bed space allocation, physician workload and a decreased IABP support time.
CONCLUSION: There is no difference in limb complications between perfusionist and physician removal of IABP catheters. The survey demonstrate an improvement in resource allocation and efficiency. A perfusionist led IABP removal program can be done safely and may help improve program efficiency.
The invention provides a recognizable portable tongue image color correction color chart and a recognition method thereof, which are used in the intelligent tongue diagnosis of traditional Chinese medicine and are used for solving the defects that the traditional tongue image color correction color chart is inconvenient to carry about, is difficult to be recognized by a computer and the like. The color card is small in size and easy to carry in consideration of convenience. But too small a size is not conducive to automatic identification by a computer. The invention adds special geometric patterns in the specific position of the color card, adds the special geometric patterns into the color card area according to the specific size and the geometric positions, and is matched with a specific improved computer identification algorithm, thereby realizing the automatic identification, positioning and color sampling of the color card by the computer and obtaining high identification rate. The invention eliminates the complicated procedure of manually calibrating the color card in color correction and improves the efficiency of color correction processing. The invention also provides a solution for errors caused by low identification rate of the intelligent tongue inspection identifier of the traditional Chinese medicine under low pixels, perspective deformation of a color chart and other factors, and obtains good effect.
The invention discloses a method, a device, a system and a medium for leading emotion, wherein the method comprises the following steps: and responding to the evaluation request, determining a first trigger instruction or a second trigger instruction, and sending the first trigger instruction or the second trigger instruction. And receiving the emotional state evaluation table, generating a first human-computer interaction interface, and acquiring first recommended grooming information or second recommended grooming information. And generating a second human-computer interaction interface, displaying the first recommended grooming scheme information or the second recommended grooming information by the second human-computer interaction interface, acquiring confirmation feedback of the first recommended grooming scheme information or the second recommended grooming information, and playing the corresponding guide file. Corresponding apparatus, systems, and storage media are also disclosed. The invention provides technical help for emotion dispersion of the user by helping the user to evaluate the current emotion state and playing the corresponding guide file according to the current emotion state of the user. The method is mainly used in the field of Internet application.